Dr. Martens plc
Other OTCRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Dr. Martens plc (LSE:DOCS) designs, develops, manufactures, markets and distributes premium footwear and accessories under the iconic Dr. Martens brand. The company offers a broad range of products including its core Originals silhouettes such as the 1460 boot, 1461 shoe, 2976 Chelsea boot and Adrian tassel loafer; fusion and casual shoes including Buzz, Zebzag, Mary Jane and Lowell; kids footwear; sandals; bags such as Weekender and Top Handle; small leather goods; and complementary accessories including shoe care products, laces and socks. Dr. Martens operates through direct-to-consumer channels comprising owned retail stores and ecommerce, alongside wholesale and distributor partnerships; it sells in more than 60 countries across three regions—EMEA, Americas and APAC—with manufacturing in the UK, China, Vietnam, Laos and Thailand. Founded with its first boot produced on 1 April 1960 in Wollaston, England, the company is headquartered in London, United Kingdom. In recent developments, Dr. Martens launched its Levers for Growth strategy in June 2025, shifting to a consumer-first approach focused on full-price sales, product innovation and market expansion; it introduced new products including the Zebzag Laceless boot, 1460 Rain boot and expansions in bags and small leather goods. The company entered the UAE market via a distribution partnership with Beside Group and expanded in Latin America through Crosby with new stores in Argentina and Chile; it also deepened wholesale partnerships in Italy, the Philippines and key markets like the US and South Korea while establishing a Global Technology Centre in India and advancing its Customer Data Platform and supply planning systems.
Dr. Martens plc (DRMTY) Q4 2026 Earnings Call Transcript
Dr Martens profits jump as turnaround gains grip
Dr. Martens plc (DRMTY) Q3 2026 Sales/Trading Call Transcript
Dr. Martens Revenue Drops on Europe, Middle East and Africa Weakness
Dr Martens sales growth slows but 'significant' profit increase still expected
Dr. Martens plc (DRMTY) Q2 2026 Earnings Call Transcript
Dr Martens drops despite results in line with forecasts
Dr Martens back on its feet
Dr Martens tiptoes higher after positive America retail trading, UK still challenging
Dr. Martens: Iconic Brand At A Potential Bargain
Dr Martens surges 23% as investors lace up for recovery story
Dr. Martens plc (DOCMF) Q4 2025 Earnings Conference Call Transcript
Dr Martens marketing 'reset' saw annual revenue and profit retreat, eyes return to growth this year
Dr Martens interims a first test for new CEO after shares stumble to all-time low
Dr. Martens Selects Amperity to Transform Customer Data Strategy
Dr. Martens plc (DOCMF) Q3 2025 Sales/ Trading Statement Call Transcript
Dr Martens flags ‘progress' as constant currency revenue grows
Dr Martens and Ryanair in focus on Monday
Dr Martens recovery plan to be tested in forthcoming update
Dr Martens redemption arc will be ‘multi-year event'